Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA6 | P23280 | 4/20 | 0.42 |
| ▸ | CA5A | P35218 | 4/20 | 0.42 |
| ▸ | CA7 | P43166 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16528 | 0.79 | GAA (0.39) | ALDH1A1MAPTGAAKDM4ELMNA | |
| SCHEMBL1156253 | 0.77 | GAA (0.38) | ALDH1A1MAPTGAAKDM4ELMNA | |
| SCHEMBL427846 | 0.77 | GAA (0.38) | ALDH1A1MAPTGAAKDM4ELMNA | |
| SCHEMBL30252450 | 0.77 | GAA (0.38) | ALDH1A1MAPTGAAKDM4ELMNA | |
| SCHEMBL20610107 | 0.73 | CA2 (0.42) | CA1CA2CA9CA12CA6 | |
| SCHEMBL111337 | 0.71 | — | — | |
| SCHEMBL29367162 | 0.71 | — | — | |
| SCHEMBL20610119 | 0.70 | CA2 (0.50) | CA1CA2CA9CA12CA6 | |
| SCHEMBL20610239 | 0.68 | NNMT (0.48) | CA1CA2CA9CA12CA6 | |
| SCHEMBL20610104 | 0.68 | NPC1 (0.40) | CA1CA2CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2022-06-28 | — | — | US | disclosed |
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2022-06-28 | — | — | US | disclosed |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-08-27 | — | — | US | disclosed |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-08-27 | — | — | US | disclosed |
| EP-3649112-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019008029-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008029-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| CN-1114598-C | Aromatic compounds and pharmaceutical compositions containing them | ZENECA LTD (GB) | 2003-07-16 | — | — | CN | disclosed |
| EP-0847391-B1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| EP-0847391-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-06-17 | — | — | EP | disclosed |
| WO-1997000864-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
| EP-0096004-B1 | SULFONYL(THIO)UREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AND/OR GROWTH REGULATING AGENTS | CIBA-GEIGY AG (CH) | 1989-04-26 | — | — | EP | disclosed |
| US-4804757-A | INTERMEDIATES FOR SULFONYLUREA HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
| US-4792608-A | HERBICIDE INTERMEDIATES | CIBA-GEIGY CORPORATION (US) | 1988-12-20 | — | — | US | disclosed |
| US-4707551-A | PLANT GROWTH REGULATORS | CIBA-GEIGY CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| US-4684730-A | HERBICIDE INTERMEDIATES | CIBA-GEIGY CORPORATION (US) | 1987-08-04 | — | — | US | disclosed |
| US-4681620-A | Sulfonylureas and sulfonylthioureas, and method of use thereof as herbicides and/or growth regulators | CIBA-GEIGY CORPORATION (US) | 1987-07-21 | — | — | US | disclosed |
| US-4612037-A | Novel sulfonylureas and sulfonylthioureas, and method of use thereof as herbicides and/or growth regulators | CIBA-GEIGY CORPORATION (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0096004-A2 | Sulfonyl(thio)ureas, process for their preparation and their use as herbicides and/or growth regulating agents | CIBA-GEIGY AG (CH) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370776-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | CA1 3881/4885CA2 2056/4885CA9 2893/4885 |
| US-20200270227-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | CA1 3881/4885CA2 2056/4885CA9 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.